{"disease":{"id":"myeloma-plasma-cell","name":"myeloma plasma cell"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05556928","title":"Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT06760052","title":"Longitudinal Data Registry of Plasma Cell Dyscrasia","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05283993","title":"A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT04566328","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1450,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT00898040","title":"Study of DNA Samples From Patients With Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT00002678","title":"Combination Chemotherapy in Treating Patients With Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":595,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT04328662","title":"A Study of Ninlaro in Real World Clinical Practice in China","phase":"","overall_status":"COMPLETED","enrollment_count":482,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00303719","title":"Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":342,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT00049673","title":"Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":332,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":true},{"nct_id":"NCT07319897","title":"A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT00544115","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05312255","title":"Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma","phase":"NA","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06333509","title":"Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":166,"lead_sponsor_name":"CARsgen Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT01415882","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03246906","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT00005792","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT03017820","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":127,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05260203","title":"MargheRITA (Remote Intelligence for Therapeutic Adherence)","phase":"NA","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Advice Pharma Group srl","has_results":false},{"nct_id":"NCT02952508","title":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Cellectar Biosciences, Inc.","has_results":false},{"nct_id":"NCT00474929","title":"Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT00003687","title":"Treatment for Chronic Pain in Patients With Advanced Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT02506959","title":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05092451","title":"Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04271644","title":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04776330","title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT00966693","title":"Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00004088","title":"Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT01372540","title":"Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04782687","title":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":73,"lead_sponsor_name":"US Oncology Research","has_results":false},{"nct_id":"NCT00723099","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT00941720","title":"Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT00448201","title":"Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT02765854","title":"Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT00006890","title":"Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT01301807","title":"Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00790842","title":"Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":63,"lead_sponsor_name":"PrECOG, LLC.","has_results":true},{"nct_id":"NCT00088855","title":"Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05153330","title":"Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":55,"lead_sponsor_name":"Biomea Fusion Inc.","has_results":false},{"nct_id":"NCT06140966","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04756401","title":"Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT00305812","title":"Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT04008888","title":"a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT01842308","title":"Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT05581875","title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT00450814","title":"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT01028716","title":"Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":46,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT00792142","title":"Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"City of Hope Medical Center","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}